Figure 2
Figure 2. ALK1Fc causes vascular and lymphatic defects. (A) Isolectin-B4 (green) and SMA (red) staining of P8 retina from PBS- or ALK1Fc-treated pups (10 mg/kg; P1 P3, P5). (B) Analysis of lymphatic function by dextran–FITC injection into the tail tip () of a P5 pup treated with PBS or ALK1Fc (10 mg/kg, P1 and P3). Images were captured 5 minutes after injection. (Top) Drainage of dextran–FITC into the collecting lymphatic vessel that extends the length of the tail. Scale bar represents 1 mm. (Bottom) “Honeycomb” lymphatic vessels in the dermis adjacent to the injection site (box). Scale bar represents 250 μm. (C) CD31 (blue, vasculature) and LYVE1 (red, lymphatic) staining of the tail dermis from PBS- or ALK1Fc-treated pups (10 mg/kg, P1 and P3) at P6. Scale bar represents 250 μm. (D) CD31 (blue, vasculature) and LYVE1 (red, lymphatic) staining of the intestine from PBS- or ALK1Fc-treated pups (10 mg/kg, P1 and P3) at P6. Scale bar represents 250 μm.

ALK1Fc causes vascular and lymphatic defects. (A) Isolectin-B4 (green) and SMA (red) staining of P8 retina from PBS- or ALK1Fc-treated pups (10 mg/kg; P1 P3, P5). (B) Analysis of lymphatic function by dextran–FITC injection into the tail tip () of a P5 pup treated with PBS or ALK1Fc (10 mg/kg, P1 and P3). Images were captured 5 minutes after injection. (Top) Drainage of dextran–FITC into the collecting lymphatic vessel that extends the length of the tail. Scale bar represents 1 mm. (Bottom) “Honeycomb” lymphatic vessels in the dermis adjacent to the injection site (box). Scale bar represents 250 μm. (C) CD31 (blue, vasculature) and LYVE1 (red, lymphatic) staining of the tail dermis from PBS- or ALK1Fc-treated pups (10 mg/kg, P1 and P3) at P6. Scale bar represents 250 μm. (D) CD31 (blue, vasculature) and LYVE1 (red, lymphatic) staining of the intestine from PBS- or ALK1Fc-treated pups (10 mg/kg, P1 and P3) at P6. Scale bar represents 250 μm.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal